Bristol-Myers Squibb Company (BMY) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $55.30 (-1.06%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 6, 2026 | Michael Yee | UBS | $70.00 | +26.6% |
| Feb 24, 2026 | Trung Huynh | RBC Capital | $60.00 | +8.5% |
| Feb 6, 2026 | Terence Flynn | Morgan Stanley | $40.00 | -27.7% |
| Feb 6, 2026 | Mohit Bansal | Wells Fargo | $60.00 | +8.5% |
| Jan 13, 2026 | David Risinger | Leerink Partners | $60.00 | +8.5% |
| Jan 9, 2026 | Louise Chen | Scotiabank | $60.00 | +8.5% |
| Dec 4, 2025 | Louis Chen | Scotiabank | $53.00 | -4.2% |
| Dec 3, 2025 | Srikripa Devarakonda | Truist Financial | $65.00 | +17.5% |
| Aug 5, 2025 | Narumi Nakagiri | Daiwa | $42.00 | -24.1% |
| Jul 21, 2025 | David Macdonald | Truist Financial | $84.00 | +51.9% |
| Apr 23, 2025 | Akash Tewari | Jefferies | $68.00 | +23.0% |
| Apr 22, 2025 | David Amsellem | Piper Sandler | $65.00 | +17.5% |
| Nov 12, 2024 | Evan Seigerman | BMO Capital | $61.00 | +10.3% |
| Nov 1, 2024 | Evan David Seigerman | BMO Capital | $57.00 | +3.1% |
| Sep 23, 2024 | Evan David Seigerman | BMO Capital | $48.00 | -13.2% |
| Jul 29, 2024 | Chris Shibutani | Goldman Sachs | $57.00 | +3.1% |
| Jul 29, 2024 | Carter Gould | Barclays | $41.00 | -25.9% |
| Jul 12, 2024 | Trung Huynh | UBS | $43.00 | -22.2% |
| May 16, 2024 | Steve Scala | Cowen & Co. | $67.00 | +21.2% |
| Jan 30, 2024 | James Shin | Deutsche Bank | $55.00 | -0.5% |
Top Analysts Covering BMY
BMY vs Sector & Market
| Metric | BMY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.24 | 2.40 |
| Analyst Count | 14 | 8 | 18 |
| Target Upside | +10.1% | +11475.0% | +16.8% |
| P/E Ratio | 15.53 | 3.75 | 35.47 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $46.67B | $47.01B | $47.36B | 21 |
| 2027-03-31 | $10.33B | $10.70B | $10.90B | 6 |
| 2027-06-30 | $11.00B | $11.40B | $11.61B | 6 |
| 2027-09-30 | $11.13B | $11.53B | $11.74B | 6 |
| 2027-12-31 | $11.62B | $12.03B | $12.26B | 6 |
| 2028-03-31 | $9.28B | $9.61B | $9.79B | 5 |
| 2028-06-30 | $9.52B | $9.86B | $10.05B | 5 |
| 2028-09-30 | $9.52B | $9.86B | $10.05B | 6 |
| 2028-12-31 | $9.88B | $10.23B | $10.42B | 8 |
| 2029-12-31 | $36.15B | $37.06B | $37.72B | 15 |
| 2030-12-31 | $35.50B | $36.39B | $37.04B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6.06 | $6.27 | $6.34 | 17 |
| 2027-03-31 | $1.33 | $1.39 | $1.43 | 10 |
| 2027-06-30 | $1.48 | $1.55 | $1.59 | 6 |
| 2027-09-30 | $1.46 | $1.53 | $1.56 | 7 |
| 2027-12-31 | $1.49 | $1.56 | $1.60 | 6 |
| 2028-03-31 | $1.29 | $1.35 | $1.38 | 7 |
| 2028-06-30 | $1.29 | $1.35 | $1.38 | 7 |
| 2028-09-30 | $1.27 | $1.33 | $1.36 | 12 |
| 2028-12-31 | $1.33 | $1.40 | $1.43 | 7 |
| 2029-12-31 | $4.74 | $4.89 | $5.00 | 3 |
| 2030-12-31 | $4.72 | $4.88 | $4.99 | 3 |
Frequently Asked Questions
What is the analyst consensus for BMY?
The consensus among 14 analysts covering Bristol-Myers Squibb Company (BMY) is Buy with an average price target of $62.73.
What is the highest price target for BMY?
The highest price target for BMY is $87.00, set by Evan Seigerman at BMO Capital on 2022-05-02.
What is the lowest price target for BMY?
The lowest price target for BMY is $40.00, set by Terence Flynn at Morgan Stanley on 2026-02-06.
How many analysts cover BMY?
14 analysts have issued ratings for Bristol-Myers Squibb Company in the past 12 months.
Is BMY a buy or sell right now?
Based on 14 analyst ratings, BMY has a consensus rating of Buy (2.50/5) with a +10.1% upside to the consensus target of $62.73.
What are the earnings estimates for BMY?
Analysts estimate BMY will report EPS of $6.27 for the period ending 2026-12-31, with revenue estimated at $47.01B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.